SLS — Sellas Life Sciences Group Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Sellas Life Sciences Group Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$8.12
Market Cap$1.67B
Float185.2M
Shares Outstanding186.0M
Price/Sales (TTM)26.90
vs. Analyst Target+23.2% to analyst PT
Dividend RateNone
Analyst Target Price$10.00 (3 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $1,900 -$16.8M $1,900 $26.5M
2021 $7.6M -$20.7M $7.4M -$18.3M
2022 $1.0M -$41.3M $900,000 -$31.5M
2023 N/A -$37.3M N/A $529,000
2024 N/A -$30.9M N/A $632,000
2025 N/A -$26.9M N/A -$28.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$6.6M
Sep 2025 N/A -$6.8M
Dec 2025 N/A -$7.7M
Mar 2026 N/A -$8.4M

Ownership & Float

Insider Ownership0.4%
Institutional Ownership29.2%
Short Float30.9%
% of All Funds Holding1.80%
Number of Funds Holding148

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$5.59Near-term / short-term trend
Weekly40-Week SMA$3.54Medium-term trend
Weekly80-Week SMA$2.47Cyclical trend (business cycle)
Weekly200-Week SMA$2.00Secular trend (multi-year)
Monthly10-Month SMA$3.67Near-term monthly trend
Monthly20-Month SMA$2.55Medium-term monthly trend
Monthly40-Month SMA$1.92Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$5.00 support 1.36x 0 months ago
$3.70 support 1.13x 2 months ago
$1.60 support 2.74x 4 months ago
$1.10 support 1.08x 12 months ago

Historical Earnings Reactions (72 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.14% 0.00% 44.44% 21.07% -52.57%
1 Day -2.63% -1.10% 31.94% 25.10% -53.66%
1 Week -1.86% -3.88% 34.72% 71.84% -56.91%
2 Weeks 0.91% -2.69% 42.25% 77.98% -62.87%
1 Month 1.75% -2.70% 43.66% 169.96% -82.35%

Next earnings: July 31, 2026 (64 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-0.6%50.0%18
Feb0.7%44.4%18
Mar0.1%33.3%18
Apr1.7%36.8%19
May11.8%66.7%18
Jun-14.8%27.8%18
Jul-4.0%33.3%18
Aug-6.9%33.3%18
Sep1.1%38.9%18
Oct3.7%38.9%18
Nov-1.5%33.3%18
Dec5.1%27.8%18

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.12% 41.9% 859
Tuesday 0.06% 43.3% 942
Wednesday -0.02% 41.6% 939
Thursday 0.16% 41.2% 921
Friday -0.20% 43.5% 917

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 29.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.4%

Founder-led management: Angelos Stergiou (Founder, President, CEO & Director)

12-Month Insider Activity Summary

Total Filings3
Net Value+N/A
Net Shares Change93,400
% of Float0.1%
C-Suite Filings0
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Kalin Katherine Bach +$100,806 1 1 buy
Wasman Jane +$33,800 1 1 buy
VAN NOSTRAND ROBERT L +$14,800 1 1 buy

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-11-21 Kalin Katherine Bach +$100,806 Transaction at $1.59, now +410.7%
2025-06-13 VAN NOSTRAND ROBERT L +$14,800 Transaction at $1.48, now +448.6%
2025-06-02 Wasman Jane +$33,800 Transaction at $1.69, now +380.5%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Sellas Life Sciences Group Inc (SLS) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for SLS on Trend Edge →